Hepion Pharmaceuticals

$1.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-6.93%) Today
-$0.02 (-1.06%) As of 10:42 PM UTC after-hours

Why Robinhood?

You can buy or sell HEPA and other stocks, options, and ETFs commission-free!

About HEPA

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ. The listed name for HEPA is Hepion Pharmaceuticals, Inc. Common Stock.

CEO
Robert T. Foster
Employees
12
Headquarters
Edison, New Jersey
Founded
2013
Market Cap
130.15M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
15.08M
High Today
$2.00
Low Today
$1.75
Open Price
$1.96
Volume
9.65M
52 Week High
$4.83
52 Week Low
$1.00

HEPA Earnings

-$7.48
-$4.99
-$2.49
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected May 13, After Hours

You May Also Like

CAI-A
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure